An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience
Phase of Trial: Phase IV
Latest Information Update: 14 Jul 2015
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Biomarker; Pharmacodynamics
- Acronyms FAIR
- Sponsors AbbVie
- 10 Jun 2017 Biomarkers information updated
- 14 Jul 2015 Last checked against ClinicalTrials.gov record.
- 28 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.